Background
Background Although selective Although selective serotonin reuptake inhibitors (SSRIs) are serotonin reuptake inhibitors (SSRIs) are frequently used for major depressive frequently used for major depressive disorder, only 50^60% of patients disorder, only 50^60% of patients respond to a standard dose.For non-respond to a standard dose.For nonresponders, dose escalation is often responders, dose escalation is often applied. applied.
Aim
Aim To systematically review the To systematically review the evidence for dose escalation of SSRIs. evidence for dose escalation of SSRIs.
Method Method A systematic literature search
A systematic literature search in MEDLINE, EMBASE,CINAHL and in MEDLINE,EMBASE,CINAHL and PsycInfo was performed.Randomised PsycInfo was performed.Randomised controlled trials and meta-analyses controlled trials and meta-analyses investigating dose escalation of SSRIs were investigating dose escalation of SSRIs were identified.Relevant articles were identified.Relevant articles were retrieved and critically appraised.Results retrieved and critically appraised.Results were summarised in an evidence table. were summarised in an evidence table.
Pooling was not justified because of Pooling was not justified because of heterogeneity of the identified studies. heterogeneity of the identified studies.
Results

Results Eighttrue dose-escalation
Eighttrue dose-escalation studies and three meta-analyses were studies and three meta-analyses were identified.The available data provided no identified.The available data provided no unequivocal base for dose escalation.Dose unequivocal base for dose escalation.Dose escalation before 4 weeks of treatment at escalation before 4 weeks of treatment at a standard dose appeared to be a standard dose appeared to be ineffective. ineffective.
Conclusions Conclusions Dose escalation of SSRIs
Dose escalation of SSRIs is equivocally supported by evidence of is equivocally supported by evidence of randomised controlled trials; randomised controlled trials; methodological difficulties in the studies methodological difficulties in the studies may account for this lack of evidence. may account for this lack of evidence.
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So far many countries have developed na-So far many countries have developed national clinical guidelines for the treatment tional clinical guidelines for the treatment of major depressive disorder (Depression of major depressive disorder (Depression Guideline Panel, 1993 Guideline Panel, 1993a Rush ; Rush et al et al, , 1998; Mulrow 1998; Mulrow et al et al, 1999; American , 1999; American Psychiatric Association, 2000; Anderson Psychiatric Association, 2000; Anderson et al et al, 2000; Kennedy , 2000; Kennedy et al et al, 2001; National , 2001 ; National Institute for Clinical Excellence, 2004) . In Institute for Clinical Excellence, 2004) . In these guidelines pharmacotherapy is among these guidelines pharmacotherapy is among the most important treatments, and in the most important treatments, and in many countries selective serotonin reuptake many countries selective serotonin reuptake inhibitors (SSRIs) have become the first-line inhibitors (SSRIs) have become the first-line antidepressants. It is less clear what should antidepressants. It is less clear what should be done in those 40-50% of patients who be done in those 40-50% of patients who do not respond to the first antidepressant do not respond to the first antidepressant administered (Thase & Rush, 1995; administered (Thase & Rush, 1995; Kroenke Kroenke et al et al, 2001) . Strategies in case of , 2001). Strategies in case of non-response have been published in non-response have been published in several narrative reviews (Thase & Rush, several narrative reviews (Thase & Rush, 1997; Nelson, 1998; Crismon 1997; Nelson, 1998; Crismon et al et al, 1999; , 1999; Fava, 2000 Fava, 2000a O'Reardon ; O'Reardon et al et al, 2000; , 2000; Marangell, 2001; Trivedi & Kleiber, Marangell, 2001; Trivedi & Kleiber, 2001; Hirschfeld 2001; Hirschfeld et al et al, 2002; Kennedy , 2002; Kennedy et et al al, 2002; Anderson, 2003; Kennedy & , 2002; Anderson, 2003; Kennedy & McDonough, 2003; McIntyre McDonough, 2003; McIntyre et al et al, 2003; and in one systematic review and in one systematic review (Stimpson (Stimpson et al et al, 2002) . Three major strate-, 2002) . Three major strategies for non-response are recommended: gies for non-response are recommended: dose escalation, augmenting the antidepres-dose escalation, augmenting the antidepressant by adding a second drug, and switch-sant by adding a second drug, and switching to another antidepressant of the same ing to another antidepressant of the same or a different class. or a different class.
Available dose-finding studies do not Available dose-finding studies do not provide evidence for initiating pharmaco-provide evidence for initiating pharmacotherapy for major depressive disorder with therapy for major depressive disorder with SSRIs in higher than standard doses SSRIs in higher than standard doses (Altamura (Altamura et al et al, 1988; Beasley , 1988; Beasley et al et al, 1990; , 1990; Dunner & Dunbar, 1992; Tignol Dunner & Dunbar, 1992; Tignol et al et al, , 1992; Montgomery 1992; Montgomery et al et al, 1994) . For non-, 1994) . For nonresponders, all guidelines recommend dose responders, all guidelines recommend dose escalation as the appropriate strategy, escalation as the appropriate strategy, instead of continuing an apparently in-instead of continuing an apparently inadequate regimen (Depression Guideline adequate regimen (Depression Guideline Panel, 1993 Panel, 1993a ; b b; Rush ; Rush et al et al, 1998; Mulrow , 1998; Mulrow et al et al, 1999; American Psychiatric Associa-, 1999; American Psychiatric Association, 2000; Anderson tion, 2000; Anderson et al et al, 2000; Kennedy , 2000; Kennedy et al et al, 2001) . Only the National Institute for , 2001). Only the National Institute for Clinical Excellence (NICE) guideline is less Clinical Excellence (NICE) guideline is less definite (National Institute for Clinical Ex-definite (National Institute for Clinical Excellence, 2004) , advising that if 'there are cellence, 2004) , advising that if 'there are no significant side-effects, a gradual in-no significant side-effects, a gradual increase in dose should be considered'. More-crease in dose should be considered'. Moreover, surprisingly little systematic evidence over, surprisingly little systematic evidence is provided to support these recommenda-is provided to support these recommendations. Because of the above recommenda-tions. Because of the above recommendations and because of its simplicity, dose tions and because of its simplicity, dose escalation is widely practised and often the escalation is widely practised and often the first strategy applied (Byrne & Rothschild, first strategy applied (Byrne & Rothschild, 1997; Shergill & Katona, 1997; Fredman 1997; Shergill & Katona, 1997; Fredman et et al al, 2000; Mischoulon , 2000; Mischoulon et al et al, 2000) . The aim , 2000) . The aim of our study was to systematically review of our study was to systematically review the evidence for dose escalation of SSRIs in the evidence for dose escalation of SSRIs in major depressive disorder. major depressive disorder.
METHOD METHOD
Design of studies to be included Design of studies to be included Ideally the design of dose-escalation studies Ideally the design of dose-escalation studies is randomisation of non-responders to is randomisation of non-responders to higher doses of an antidepressant or higher doses of an antidepressant or placebo after some weeks of a standard-placebo after some weeks of a standarddose regimen. In this review we consider dose regimen. In this review we consider three other methodological requirements three other methodological requirements for such studies. First, dose escalation for such studies. First, dose escalation should be deferred to 3-6 weeks after should be deferred to 3-6 weeks after initiation of treatment, because several initiation of treatment, because several weeks are required for antidepressants to weeks are required for antidepressants to have clinical effect (Mischoulon, 1997) . have clinical effect (Mischoulon, 1997) . The practice of dose escalation and the The practice of dose escalation and the demonstration of a dose-response relation-demonstration of a dose-response relationship is based on selection of 'true' non-ship is based on selection of 'true' nonresponders (Baker & Woods, 2003) . As this responders (Baker & Woods, 2003) . As this might take 6-10 weeks (Quitkin might take 6-10 weeks (Quitkin et al et al, , 2003) , dose-escalation studies with early 2003), dose-escalation studies with early randomisation diminish the possibility of randomisation diminish the possibility of proving the usefulness of dose escalation. proving the usefulness of dose escalation. The inclusion of unidentified late respon-The inclusion of unidentified late responders in both arms of the study reduces the ders in both arms of the study reduces the contrast between the intervention and contrast between the intervention and control. Second, an outstanding study will control. Second, an outstanding study will have sufficient power to be able to demon-have sufficient power to be able to demonstrate a clinically relevant difference (e.g. strate a clinically relevant difference (e.g. 20%) between treatment arms and, third, 20%) between treatment arms and, third, will describe the method of dose escalation will describe the method of dose escalation and describe the early drop-out rates and describe the early drop-out rates because of dose escalation. because of dose escalation. ( 2 0 0 6 ) , 1 8 9, 3 0 9^3 1 6 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 5 . 0 1 8 3 2 5
Identification and selection Identification and selection of articles of articles
( 2 0 0 6 ) , 1 8 9, 3 0 9^3 1 6 . d o i : 1 0 . 11 9 2 / b j p . b p . 1 0 5 . 0 1 8 3 2 5 [MeSH] , in combination with the Cochrane Collaboration search-with the Cochrane Collaboration searchfilter for randomised controlled trials filter for randomised controlled trials and systematic reviews, the Cochrane and systematic reviews, the Cochrane Collaboration Depression Anxiety and Collaboration Depression Anxiety and Neurosis group search-filter for major de-Neurosis group search-filter for major depressive disorder and MeSH-terms and text pressive disorder and MeSH-terms and text words for SSRIs. Primary selection (inde-words for SSRIs. Primary selection (independently by H.R. and J.H.) was based on pendently by H.R. and J.H.) was based on design and focused on dose-response design and focused on dose-response relationships for SSRIs, by screening title relationships for SSRIs, by screening title and abstract of the article. and abstract of the article. Agreement on Agreement on exclusion of irrelevant articles exclusion of irrelevant articles was 99.1%, was 99.1%, with Cohen's kappa for interrater agree-with Cohen's kappa for interrater agreement 0.62 (which is a substantial agree-ment 0.62 (which is a substantial agreement (Munoz & Bangdiwala, 1997) ). ment (Munoz & Bangdiwala, 1997) ). Discrepancies between initial selection were Discrepancies between initial selection were resolved by discussion and consensus. resolved by discussion and consensus.
Second, all potentially relevant articles Second, all potentially relevant articles were judged according to specific inclusion were judged according to specific inclusion and exclusion criteria (criteria available from and exclusion criteria (criteria available from H.R. on request). In case of doubt, an article H.R. on request). In case of doubt, an article was read fully and assigned afterwards. was read fully and assigned afterwards. Additionally, relevant cross-references were Additionally, relevant cross-references were retrieved. Double publications were con-retrieved. Double publications were considered together to reveal the maximum sidered together to reveal the maximum available information. available information.
Critical appraisal and summary Critical appraisal and summary
Next, selected articles were critically Next, selected articles were critically appraised and abstracted by H.R., using appraised and abstracted by H.R., using standardised forms derived from the Dutch standardised forms derived from the Dutch Institute of Healthcare Improvement Institute of Healthcare Improvement (Kwaliteitsinstituut voor de Gezondheidszorg (Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2000) and the Agency for Healthcare CBO, 2000) and the Agency for Healthcare Policy and Research (Mulrow Policy and Research (Mulrow et al et al, 1999) . , 1999). The items used for critical appraisal were The items used for critical appraisal were the same as proposed by the Scottish Inter-the same as proposed by the Scottish Intercollegiate Guideline Network (2001) and collegiate Guideline Network (2001) and Sackett Sackett et al et al (2000) . Each study was (2000) . Each study was assigned a 'level of evidence' (Table 1) . assigned a 'level of evidence' ( Table 1) . Levels of evidence were based on the Levels of evidence were based on the methodological robustness of studies. For methodological robustness of studies. For the results, the highest level of evidence of the results, the highest level of evidence of the supporting scientific evidence (A1-D) the supporting scientific evidence (A1-D) was used. was used.
To assess judgement bias of the person To assess judgement bias of the person who performed the critical appraisal, inter-who performed the critical appraisal, interrater variation was determined in a slightly rater variation was determined in a slightly different set of 12 publications. We all different set of 12 publications. We all critically appraised four publications, and critically appraised four publications, and agreement for the appraisal items was ex-agreement for the appraisal items was expressed by Cohen's kappa. Kappa values pressed by Cohen's kappa. Kappa values were 0.49 (for validity of the study), 0.86 were 0.49 (for validity of the study), 0.86 (for concealment of allocation); complete (for concealment of allocation); complete agreement existed for randomisation of the agreement existed for randomisation of the study, level of evidence and data extraction study, level of evidence and data extraction (kappa (kappa¼1.0). This is in line with other re-1.0). This is in line with other reports of interrater agreement in appraisal of ports of interrater agreement in appraisal of psychiatric research (Moncrieff psychiatric research (Moncrieff et al et al, 2001) . , 2001). A qualitative summary with discussion A qualitative summary with discussion of the results, restrictions, methodological of the results, restrictions, methodological flaws and external validity of the studies flaws and external validity of the studies was described in an evidence table and a was described in an evidence table and a separate document, of which a summary separate document, of which a summary is provided in this paper. Because of the is provided in this paper. Because of the apparent heterogeneity in timing of the apparent heterogeneity in timing of the dose escalation between the studies, results dose escalation between the studies, results were not pooled in a meta-analysis. were not pooled in a meta-analysis.
RESULTS RESULTS
Search results and selection of studies are Search results and selection of studies are presented in Fig. 1 . The 11 studies selected presented in Fig. 1 . The 11 studies selected for this review are summarised in Table 2 . for this review are summarised in Table 2 
Characteristics of the studies Characteristics of the studies
Our searches identified eight dose-escalation Our searches identified eight dose-escalation studies that increased dosages after at least studies that increased dosages after at least 3 weeks of standard dosage (Dornseif 3 weeks of standard dosage (Dornseif et al et al, , 1989; Schweizer 1989; Schweizer et al et al, 1990 Schweizer et al et al, , 2001 Fava , 1990 Fava , , 2001 Fava et et al al, 1992 Fava et et al al, , 1994 Fava et et al al, , 2002 Benkert , 1992 Benkert , , 1994 Benkert , , 2002 Benkert et al et al, 1997; , 1997; Licht & Qvitzau, 2002) . We further found Licht & Qvitzau, 2002) . We further found three systematic reviews about dose-three systematic reviews about doseresponse relationships, which included, re-response relationships, which included, respectively, three (Bollini spectively, three (Bollini et al et al, 1999) , three , 1999), three (Corruble & Guelfi, 2000) and four (Baker Across the studies different outcome de-Across the studies different outcome definitions for end-points were used. In seven finitions for end-points were used. In seven articles, response was defined as a reduction articles, response was defined as a reduction of of 5 550% in the Hamilton Rating Scale for 50% in the Hamilton Rating Scale for Depression (HRSD) score (Dornseif Depression (HRSD) score (Dornseif et al et al, , 1989; Schweizer 1989; Schweizer et al et al, 1990; Benkert , 1990; Benkert et al et al, , 1997; Licht & Qvitzau, 2002; Baker 1997; Licht & Qvitzau, 2002; Baker et al et al, , 2003) . A Clinical Global Impression (CGI) 2003). A Clinical Global Impression (CGI) improvement or severity score improvement or severity score 4 42 was used 2 was used for response in one study (Schweizer for response in one study (Schweizer et al et al, , 2001) . Partial response was used in three 2001). Partial response was used in three studies and defined as 25-50% decrease studies and defined as 25-50% decrease in HRSD score (Fava in HRSD score (Fava et al et al, 1992 (Fava et al et al, , 1994 (Fava et al et al, , , 1992 (Fava et al et al, , 1994 (Fava et al et al, , 2002 . In seven studies, remission-rates 2002). In seven studies, remission-rates were reported. These were defined as were reported. These were defined as HRSD score HRSD score 4 47 (Fava 7 (Fava et al et al, 1994 , 2002 , 1994 , 2002 Licht & Qvitzau, 2002) NNT NNT all all ¼4 (1.64 NNT NNT all all ¼6 (2.46 RCT, randomised controlled trial; SE, side-effects; SME, SSRI mg-equivalents. CIT, citalopram; FLX, fluoxetine; IMI, imipramine; PAR, paroxetine; PLAC, placebo; SER, sertraline; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic RCT, randomised controlled trial; SE, side-effects; SME, SSRI mg-equivalents. CIT, citalopram; FLX, fluoxetine; IMI, imipramine; PAR, paroxetine; PLAC, placebo; SER, sertraline; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. antidepressant.
score (Dornseif score (Dornseif et al et al, 1989; Schweizer , 1989; Schweizer et al et al, , 1990; Fava 1990; Fava et al et al, 1994 Fava et al et al, , 2002 or no re-, 1994, 2002) or no remission (HRSD score mission (HRSD score 4 48 (Schweizer 8 (Schweizer et al et al, , 2001) ). In the present studies no genetic 2001)). In the present studies no genetic information of the cytochrome P450 information of the cytochrome P450 (CYP) system nor drug blood levels were (CYP) system nor drug blood levels were reported. reported.
The three previous reviews all had some The three previous reviews all had some methodological problems: Bollini methodological problems: Bollini et al et al (1999) pooled studies with completely (1999) pooled studies with completely different designs and drug classes, and different designs and drug classes, and applied a dose equivalence strategy that applied a dose equivalence strategy that put differential doses of SSRIs together. put differential doses of SSRIs together. Baker Baker et al et al (2003) also pooled hetero-(2003) also pooled heterogeneous studies with different moments of geneous studies with different moments of dose escalation, and used an unusually dose escalation, and used an unusually low reference dose of fluoxetine (5 mg). low reference dose of fluoxetine (5 mg). Corruble & Guelfi (2000) did not use an Corruble & Guelfi (2000) did not use an adequate search strategy and only described adequate search strategy and only described the dose-response relationships found in the dose-response relationships found in their identified studies as flat, curvilinear their identified studies as flat, curvilinear or linear. or linear.
We will briefly outline the dose-We will briefly outline the doseescalation studies. Dorseif escalation studies. Dorseif et al et al (1989) first (1989) first investigated week-3 non-responders investigated
week-3 non-responders ( (n n¼371 out-patients) to fluoxetine, who 371 out-patients) to fluoxetine, who were randomised to continuation with were randomised to continuation with 20 mg or increase to 60 mg/day for 5 weeks. 20 mg or increase to 60 mg/day for 5 weeks. Response rates were 40.5% and 44.7%, Response rates were 40.5% and 44.7%, respectively, and remission rates 33.3% respectively, and remission rates 33.3% and 36.2%, respectively. Drop-out rates and 36.2%, respectively. Drop-out rates because of side-effects were significantly because of side-effects were significantly different at 5.3% and 11.6%, respectively. different at 5.3% and 11.6%, respectively. Schweizer Schweizer et al et al (1990) investigated 77 (1990) investigated 77 non-responsive out-patients after 3 weeks' non-responsive out-patients after 3 weeks' administration of fluoxetine (20 mg/day), administration of fluoxetine (20 mg/day), with a randomisation to placebo increase with a randomisation to placebo increase or dose escalation up to 60 mg/day for 5 or dose escalation up to 60 mg/day for 5 weeks. Response rates were 51.2% and weeks. Response rates were 51.2% and 50%, respectively, with non-significant 50%, respectively, with non-significant drop-out rates of 4.9% drop-out rates of 4.9% v v. 16.7%. In a simi-. 16.7%. In a similar study, Schweizer lar study, Schweizer et al et al (2001) studied (2001) studied dose escalation of sertraline in out-patient dose escalation of sertraline in out-patient non-remitters after 3 weeks of sertraline non-remitters after 3 weeks of sertraline (50 mg/day, (50 mg/day, n n¼75). Doses were randomly 75). Doses were randomly either kept at 50 mg/day or increased to either kept at 50 mg/day or increased to 150 mg/day. Remission rates after 5 weeks 150 mg/day. Remission rates after 5 weeks were 32% and 47%, respectively (non-were 32% and 47%, respectively (nonsignificant). Specified drop-out rates significant). Specified drop-out rates because of side-effects were not reported. because of side-effects were not reported.
Fava Fava et al et al (1992) first openly treated (1992) first openly treated 15 out-patients (who were week-8 non-15 out-patients (who were week-8 nonresponders to fluoxetine at 20 mg/day) with responders to fluoxetine at 20 mg/day) with increased doses of fluoxetine titrated up to increased doses of fluoxetine titrated up to 80 mg/day for 4 weeks. No response rates 80 mg/day for 4 weeks. No response rates were given, but the mean 17-item HRSD were given, but the mean 17-item HRSD score score decreased 6.2 points in week-8 decreased 6.2 points in week-8 non-non-responders and 10.1 points in partial responders and 10.1 points in partial responders. In a second study, Fava responders. In a second study, Fava et al et al (1994) randomised week-8 non-responders (1994) randomised week-8 non-responders to fluoxetine 20 mg/day ( to fluoxetine 20 mg/day (n n¼41) to either 41) to either fluoxetine 40-60 mg, desipramine addition fluoxetine 40-60 mg, desipramine addition or lithium addition for 4 weeks. No or lithium addition for 4 weeks. No placebo increase was practised. Remission placebo increase was practised. Remission rates were 53%, 25% and 29%, res-rates were 53%, 25% and 29%, respectively, but these differences were non-pectively, but these differences were nonsignificant. Initial partial responders significant. Initial partial responders appeared to benefit most from fluoxetine appeared to benefit most from fluoxetine dose increases (data non-significant). dose increases (data non-significant). Drop-out rates for side-effects were 0%, Drop-out rates for side-effects were 0%, 17% and 7%, respectively. In a third 17% and 7%, respectively. In a third study, study, Fava Fava et al et al (2002) repeated the (2002) repeated the three-arm three-arm randomised design from their 1994 study randomised design from their 1994 study with a stratification for partial or non-with a stratification for partial or nonresponse at week 8 ( response at week 8 (n n¼101). After 4 weeks, 101). After 4 weeks, the high-dose fluoxetine group showed in-the high-dose fluoxetine group showed increased but non-significant remission rates creased but non-significant remission rates (42.4%) compared with desipramine addi-(42.4%) compared with desipramine addition (29.4%) and lithium addition tion (29.4%) and lithium addition (23.5%). Again initial partial responders (23.5%). Again initial partial responders appeared to benefit more from fluoxetine appeared to benefit more from fluoxetine dose increases compared with dose increases compared with initial non-initial nonresponders (differences non-responders (differences non-significant). significant).
No
No specific data on drop-out because of specific data on drop-out because of side-side-effects were given. effects were given. Benkert Benkert et al et al (1997) investigated dose (1997) investigated dose escalation of paroxetine (20 mg/day) in escalation of paroxetine (20 mg/day) in out-patients who were depressed or had out-patients who were depressed or had minor depression. Those who did not re-minor depression. Those who did not respond after 3 weeks of treatment ( spond after 3 weeks of treatment (n n¼86) 86) were randomised to receive 40 mg paroxe-were randomised to receive 40 mg paroxetine for 3 additional weeks or placebo tine for 3 additional weeks or placebo increase. Response rates were 75% in the increase. Response rates were 75% in the placebo increased group and 74% in the placebo increased group and 74% in the . sertraline 100 mg/day (placebo increase) sertraline 100 mg/day (placebo increase) or mianserin addition in 295 out-or mianserin addition in 295 outpatients non-responsive to sertraline patients non-responsive to sertraline 50 mg for 4 weeks and additionally in-50 mg for 4 weeks and additionally increased to 100 mg for 2 more weeks. creased to 100 mg for 2 more weeks. Response rates 5 weeks after randomis-Response rates 5 weeks after randomisation were significantly lower in the ation were significantly lower in the dose-increase group (56%) than in the dose-increase group (56%) than in the sertraline 100 mg group (70%) and sertraline 100 mg group (70%) and the mianserin addition group (67%). the mianserin addition group (67%). Data on drop-out because of side-effects Data on drop-out because of side-effects were not specified. were not specified.
Strengths, flaws and other details of all Strengths, flaws and other details of all selected studies are shown in Table 2 . In selected studies are shown in Table 2 . In summary, we mention several methodo-summary, we mention several methodological problems we encountered: absence logical problems we encountered: absence of placebo controls (Fava of placebo controls (Fava et al et al, 1992 (Fava et al et al, , , 1992 (Fava et al et al, , 1994 (Fava et al et al, , 2002 al, 1990 , 2001 Fava , 1990 Fava , , 2001 Fava et al et al, 1992 Fava et al et al, , 1994 Fava et al et al, , , 1992 Fava et al et al, , 1994 Fava et al et al, , 2002 , 2003) . None of the studies provided information about the studies provided information about the method of dose escalation or described method of dose escalation or described the early drop-out rates because of dose the early drop-out rates because of dose escalation. escalation.
Evidence for dose escalation? Evidence for dose escalation?
From four of the eight dose-escalation stu-From four of the eight dose-escalation studies it appeared that dose increments before dies it appeared that dose increments before 4 weeks were not effective (level of evi-4 weeks were not effective (level of evidence: A2) (Dornseif dence: A2) (Dornseif et al et al, 1989; Schweizer , 1989; Schweizer et al et al, 1990 Schweizer et al et al, , 2001 Benkert , 1990 Benkert , , 2001 (2003) proposed that differential drop-out (2003) proposed that differential drop-out because of side-effects in the dose-because of side-effects in the doseescalation group (compared with placebo escalation group (compared with placebo increase) conferred a substantial (negative) increase) conferred a substantial (negative) bias to the potential dose-response re-bias to the potential dose-response relationship. They argued that by applying a lationship. They argued that by applying a last-observation-carried-forward approach last-observation-carried-forward approach (often used in the original studies), more (often used in the original studies), more participants dropping out early (because participants dropping out early (because of side-effects) in the high-dose groups of side-effects) in the high-dose groups would unequally increase average severity would unequally increase average severity scores and decrease response rates compared scores and decrease response rates compared with the lower-dose (or placebo) groups. with the lower-dose (or placebo) groups. This methodological problem could be This methodological problem could be overcome by analysing only dose-tolerant overcome by analysing only dose-tolerant participants (those not dropping out because participants (those not dropping out because of side-effects). of side-effects).
In the well-performed study with ser-In the well-performed study with sertraline by Licht & Qvitzau (2002) (not traline by Licht & Qvitzau (2002) (not included in the three reviews), dose escala-included in the three reviews), dose escalation after 6 weeks was found to be less tion after 6 weeks was found to be less effective than continuation of the standard effective than continuation of the standard dose, or augmentation with mianserin (level dose, or augmentation with mianserin (level of evidence: A2). After 8 weeks of treat-of evidence: A2). After 8 weeks of treatment, increased dosages of fluoxetine were ment, increased dosages of fluoxetine were more effective than augmentation with more effective than augmentation with lithium or desipramine (Fava lithium or desipramine (Fava et al et al, 1994 (Fava et al et al, , , 1994 (Fava et al et al, , 2002 , although in the latter study this 2002), although in the latter study this was not significant (level of evidence: B). was not significant (level of evidence: B). In these studies no placebo dose escalation In these studies no placebo dose escalation was performed. Both studies showed a was performed. Both studies showed a non-significant trend of increased efficacy non-significant trend of increased efficacy of dose escalation compared with augmen-of dose escalation compared with augmentation (lithium or desipramine), particularly tation (lithium or desipramine), particularly for partial responders (level of evidence: B). for partial responders (level of evidence: B).
Across all studies, higher doses were re-Across all studies, higher doses were related to increased drop-out rates, which lated to increased drop-out rates, which were associated with more side-effects in were associated with more side-effects in some studies (level of evidence: A2) (Bollini some studies (level of evidence: A2) (Bollini et al et al, 1999) . It appeared that the occurrence , 1999). It appeared that the occurrence of side-effects did not increase equally of side-effects did not increase equally when dosages were gradually escalated for when dosages were gradually escalated for initial non-responders, compared with initial non-responders, compared with fixed-dose trials. However, this could not fixed-dose trials. However, this could not be compared straightforwardly between be compared straightforwardly between the studies, and was not investigated the studies, and was not investigated specifically. specifically.
Additional concerns for clinicians Additional concerns for clinicians
We identified no evidence to recommend We identified no evidence to recommend how dose increase should be practised. how dose increase should be practised. Also, the maximum dosage to be achieved Also, the maximum dosage to be achieved was not investigated well. was not investigated well.
DISCUSSION DISCUSSION
Our systematic review provided eight Our systematic review provided eight studies about dose escalation of SSRIs. studies about dose escalation of SSRIs. Only one of these studies approached our Only one of these studies approached our rather stringent criteria (Licht & Qvitzau, rather stringent criteria (Licht & Qvitzau, 2002) . We found no evidence of increased 2002). We found no evidence of increased efficacy by dose escalation within the first efficacy by dose escalation within the first 4 weeks. Dose escalation after 6 weeks 4 weeks. Dose escalation after 6 weeks appeared less effective than continuing the appeared less effective than continuing the same dose. We found some, but limited, same dose. We found some, but limited, evidence for efficacy of dose escalation evidence for efficacy of dose escalation after 8 weeks, particularly in partial re-after 8 weeks, particularly in partial responders. This effect was seen within 4 sponders. This effect was seen within 4 weeks after dose escalation. Irrespective of weeks after dose escalation. Irrespective of efficacy, dose escalation unequivocally in-efficacy, dose escalation unequivocally increased side-effects, but effects on drop-creased side-effects, but effects on dropout rates because of side-effects were less out rates because of side-effects were less straightforward. Thus, in the absence of straightforward. Thus, in the absence of methodologically well-designed studies we methodologically well-designed studies we can neither unequivocally state that dose can neither unequivocally state that dose escalation is useful nor discard it as useless. escalation is useful nor discard it as useless.
These findings may challenge the These findings may challenge the current beliefs and recommendations about current beliefs and recommendations about dose escalation as it is generally practised dose escalation as it is generally practised (Byrne & Rothschild, 1997; Shergill & (Byrne & Rothschild, 1997; Shergill & Katona, 1997; Fredman Katona, 1997; Fredman et al et al, 2000; , 2000; Mischoulon Mischoulon et al et al, 2000) . Contrary to this , 2000). Contrary to this challenge, many patients who have only challenge, many patients who have only partially responded are too often treated partially responded are too often treated with long-term obviously insufficient treat-with long-term obviously insufficient treatments (e.g. standard doses of SSRIs). For ments (e.g. standard doses of SSRIs). For these patients, one could argue that it is these patients, one could argue that it is better to try dose escalation than to con-better to try dose escalation than to continue inadequate treatment. Presumably, tinue inadequate treatment. Presumably, in the absence of clear guidance from trial in the absence of clear guidance from trial data, clinicians do not have many alterna-data, clinicians do not have many alternatives for non-responders or partial tives for non-responders or partial responders, and clinicians all have their responders, and clinicians all have their case histories of improvement after dose case histories of improvement after dose escalation. A more sophisticated question escalation. A more sophisticated question must therefore also be asked; i.e. which must therefore also be asked; i.e. which subgroup of patients will benefit from dose subgroup of patients will benefit from dose escalation? escalation?
So far, only the NICE guideline dis-So far, only the NICE guideline displayed some reserve in the general re-played some reserve in the general recommendation about dose escalation commendation about dose escalation (National Institute for Clinical Excellence, (National Institute for Clinical Excellence, 2004 , 2004) . From this report it was unclear which studies this report it was unclear which studies were taken as evidence. Three previous re-were taken as evidence. Three previous reviews concerning higher doses of anti-views concerning higher doses of antidepressants were published (Bollini depressants were published (Bollini et al et al, , 1999; Corruble & Guelfi, 2000; Baker 1999; Corruble & Guelfi, 2000; Baker et et al al, 2003) , the methodological shortcomings , 2003), the methodological shortcomings of which have already been mentioned. of which have already been mentioned. The findings in these reviews previously The findings in these reviews previously challenged the belief of a dose-response challenged the belief of a dose-response relationship, but Baker relationship, but Baker et al et al proposed a po-proposed a potential dose-response relationship, accord-tential dose-response relationship, according to their dose-tolerance analysis. All ing to their dose-tolerance analysis. All reports summarised studies performed until reports summarised studies performed until 1997; thereafter, the study by Licht & 1997;  thereafter, the study by Licht & Qvitzau (2002) further challenged the Qvitzau (2002) further challenged the efficacy of dose escalation. efficacy of dose escalation.
Limitations of the identified studies Limitations of the identified studies
Four major issues of concern in the eight Four major issues of concern in the eight identified studies should be mentioned. identified studies should be mentioned. First, the methodological quality of these First, the methodological quality of these studies varied between poor and good studies varied between poor and good according to our classification. We according to our classification. We summarised these methodological problems summarised these methodological problems in the Results section and Table 2.  in the Results section and Table 2 .
Second, and more in general, all dose-Second, and more in general, all doseescalation studies, except the studies of escalation studies, except the studies of Fava and colleagues, which lacked a Fava and colleagues, which lacked a placebo control (Fava placebo control (Fava et al et al, 1992 (Fava et al et al, , 1994 (Fava et al et al, , , 1992 (Fava et al et al, , 1994 (Fava et al et al, , 2002 , suffered a methodological problem 2002), suffered a methodological problem in the timing of dose escalation (Baker & in the timing of dose escalation (Baker & Woods, 2003) . Even the most robust study, Woods, 2003) . Even the most robust study, by Licht & Qvitzau (2002) , hampered its by Licht & Qvitzau (2002) , hampered its own design by a non-randomised dose own design by a non-randomised dose increase 2 weeks before randomisation. increase 2 weeks before randomisation. This problem might explain the high This problem might explain the high placebo response rates in some of the placebo response rates in some of the dose-escalation studies (up to 75%). dose-escalation studies (up to 75%).
Third, in most studies no data were Third, in most studies no data were provided on the selective drop-out, nor provided on the selective drop-out, nor the schedule of dose increments (Baker & the schedule of dose increments (Baker & Woods, 2003) . The possibility that patients Woods, 2003) . The possibility that patients randomised to true dose escalation might randomised to true dose escalation might drop out more frequently and earlier after drop out more frequently and earlier after randomisation (with associated high sever-randomisation (with associated high severity scores), compared with those receiving ity scores), compared with those receiving placebo, might have biased the intention-placebo, might have biased the intentionto-treat analyses in which last observations to-treat analyses in which last observations are usually carried forward to study end-are usually carried forward to study endpoints. This happens in particular when points. This happens in particular when dose escalation is performed rapidly. The dose escalation is performed rapidly. The analysis of a dose-tolerant sample in such analysis of a dose-tolerant sample in such studies would indeed provide additional studies would indeed provide additional information, but these data were not information, but these data were not provided. provided.
Fourth, in the selected trials, it was Fourth, in the selected trials, it was mostly response that was used as primary mostly response that was used as primary outcome, whereas currently remission of outcome, whereas currently remission of depression is the clinical aim of treatment depression is the clinical aim of treatment (Nierenberg & DeCecco, 2001) . If dose (Nierenberg & DeCecco, 2001) . If dose escalation would be effective, the question escalation would be effective, the question remains whether dose escalation will also remains whether dose escalation will also further improve initial responders that were further improve initial responders that were non-remitters. So far only 
Possible explanations Possible explanations for a dose^response relationship for a dose^response relationship
A possible explanation of the clinical obser-A possible explanation of the clinical observation that response might occur after dose vation that response might occur after dose escalation is initial lower levels of the drug escalation is initial lower levels of the drug in the bloodstream. This may be related to in the bloodstream. This may be related to increased metabolism because of genetic increased metabolism because of genetic polymorphisms of the CYP enzyme system polymorphisms of the CYP enzyme system (Bertilsson (Bertilsson et al et al, 1985; Steimer , 1985; Steimer et al et al, , 2001; Charlier 2001; Charlier et al et al, 2003; Brosen, 2004 Brosen, ). , 2003 Brosen, 2004 ). The incidence of increased metabolism by The incidence of increased metabolism by (multi-)duplicated genes of CYP 2D6 varies (multi-)duplicated genes of CYP 2D6 varies between 1-2% in White populations in between 1-2% in White populations in Sweden, 3.6% in Germany and 7-10% in Sweden, 3.6% in Germany and 7-10% in Spain and Sicily, and also varies between Spain and Sicily, and also varies between ethnic groups (e.g. 29% in Black Ethio-ethnic groups (e.g. 29% in Black Ethiopians) (Bertilsson pians) (Bertilsson et al et al, 2002) . A few studies , 2002). A few studies showed equivocal evidence for the showed equivocal evidence for the involvement of CYP polymorphisms (re-involvement of CYP polymorphisms (responsible for rapid metabolism) as an ex-sponsible for rapid metabolism) as an explanation of non-response to a standard planation of non-response to a standard dose of SSRIs (Bertilsson dose of SSRIs (Bertilsson et al  et al, 1997 , , 1997 , 2002 Steimer 2002; Steimer et al et al, 2001; Brosen, 2004; , 2001; Brosen, 2004; Kawanishi Kawanishi et al et al, 2004) . However, a clear , 2004). However, a clear relationship between blood levels of SSRIs relationship between blood levels of SSRIs and response was never found (Beasley and response was never found (Beasley et et al al, 1990; Norman , 1990; Norman et al et al, 1993; Baumann, , 1993; Baumann, 1996; Amsterdam 1996; Amsterdam et al et al, 1997; Bourdeaux , 1997; Bourdeaux et al et al, 1998; DeVane, 1998) . Perhaps genetic , 1998; DeVane, 1998) . Perhaps genetic variability of the central target of these variability of the central target of these drugs, the serotonin reuptake transporter, drugs, the serotonin reuptake transporter, may be responsible more directly for the may be responsible more directly for the effects of SSRIs (Hahn & Blakely, 2002; effects of SSRIs (Hahn & Blakely, 2002; Smits Smits et al et al, 2004 ). , 2004 .
From
From in-vitro in-vitro and and ex-vivo ex-vivo studies it studies it appears that, at higher doses, selective anti-appears that, at higher doses, selective antidepressants such as SSRIs may become depressants such as SSRIs may become dual-action agents that, like noradrenaline, dual-action agents that, like noradrenaline, also affect other monoamine systems also affect other monoamine systems (Owens (Owens et al et al, 1997; Gorman & Sullivan, , 1997; Gorman & Sullivan, 2000; Gilmor 2000; Gilmor et al et al, 2002) . From the current , 2002). From the current data on dose escalation in SSRIs, this data on dose escalation in SSRIs, this theoretical hypothesis can neither be falsi-theoretical hypothesis can neither be falsified nor proven. In addition, we are fied nor proven. In addition, we are unaware of an acceptable method to unaware of an acceptable method to test whether specific sites of action are test whether specific sites of action are responsible for the observed treatment responsible for the observed treatment effects. effects.
Limitations of the review Limitations of the review
No meta-analysis was performed because No meta-analysis was performed because the differences in timing of dose escalation the differences in timing of dose escalation between the identified studies introduced between the identified studies introduced substantial heterogeneity. An extension of substantial heterogeneity. An extension of the meta-regression approach as performed the meta-regression approach as performed by Baker by Baker et al et al (2003) was considered in- (2003) was considered inappropriate for addressing this problem, appropriate for addressing this problem, as the number of studies gave insufficient as the number of studies gave insufficient power; moreover, gender, age, outcome power; moreover, gender, age, outcome definition and type of SSRI ideally should definition and type of SSRI ideally should be included in such a model. be included in such a model.
The grading system for studies does not The grading system for studies does not represent the appraised methodological represent the appraised methodological dimensions of evidence. This improved the dimensions of evidence. This improved the applicability of the results for busy applicability of the results for busy clinicians, but reduced their strength. clinicians, but reduced their strength.
Finally, patients studied in trials are Finally, patients studied in trials are generally selected populations, reducing generally selected populations, reducing external validity for clinical practice. All external validity for clinical practice. All identified studies excluded psychotic de-identified studies excluded psychotic depression, bipolar depression, depression in pression, bipolar depression, depression in children or adolescents and depressive dis-children or adolescents and depressive disorder with severe psychiatric and somatic order with severe psychiatric and somatic comorbidity. comorbidity.
Future dose-escalation studies Future dose-escalation studies
For future dose-escalation trials, methodo-For future dose-escalation trials, methodological issues should be considered. First, logical issues should be considered. First, for optimal contrast in the study, an appro-for optimal contrast in the study, an appropriate group of non-responders should be priate group of non-responders should be selected by postponing randomisation and selected by postponing randomisation and refraining from (additional) interventions refraining from (additional) interventions before dose escalation is applied. The mini-before dose escalation is applied. The minimum period that can be reconciled with mum period that can be reconciled with recommendations in current guidelines recommendations in current guidelines and that is acceptable for clinical practice and that is acceptable for clinical practice is 6 weeks. Second, studies should have is 6 weeks. Second, studies should have enough power to detect significant differ-enough power to detect significant differences. This implies a large sample to start ences. This implies a large sample to start with, as approximately 50% of patients with, as approximately 50% of patients will show a response in the first 6 weeks. will show a response in the first 6 weeks. Third, the method of dose escalation should Third, the method of dose escalation should be described and applied in such a way that be described and applied in such a way that few patients drop out. Fourth, adequate few patients drop out. Fourth, adequate results should be presented: response and results should be presented: response and remission rates in intention-to-treat ana-remission rates in intention-to-treat analyses and for the group that could be lyses and for the group that could be described as dose tolerant. Fifth, efficacy described as dose tolerant. Fifth, efficacy should be tested in predefined subgroups should be tested in predefined subgroups (e.g. partial responders at week 6). Sixth, (e.g. partial responders at week 6). Sixth, genetic sampling (e.g. CYP and SERT genetic sampling (e.g. CYP and SERT polymorphisms) and plasma SSRI-level polymorphisms) and plasma SSRI-level sampling would be interesting in the further sampling would be interesting in the further examination of potential explanations for the examination of potential explanations for the clinically observed efficacy of dose escalation, clinically observed efficacy of dose escalation, and to identify potential prognostic variables. and to identify potential prognostic variables. (1988) The evidence for 20 mg a day of fluoxetine as
The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. the optimal dose in the treatment of depression. Advances in Psychiatric Treatment Treatment, , 9 9, 11^20. , 11^20. High-dose fluoxetine in the treatment of depressed High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. patients not responsive to a standard dose of fluoxetine. 
Double-blind study of high-dose fluoxetine versus Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in lithium or desipramine augmentation of fluoxetine in partial responders and non-responders to fluoxetine. partial responders and non-responders to fluoxetine. Kawanishi, C., Lundgren, S., Agren, H., Kawanishi, C., Lundgren, S., Agren, H., et al et al ( 
Similar effectiveness of paroxetine, fluoxetine, and Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. sertraline in primary care: a randomized trial. JAMA JAMA, , 286 286, 2947^2955. , 2947^2955. Montgomery, S. A., Pedersen,V., Tanghoj, P., Montgomery, S. A., Pedersen,V., Tanghoj, P., et al et al (1994) (1994) The optimal dosing regimen for citalopram^a
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